Source: Sacramento, CA, 10/23/2015 /SubmitPressRelease123
The U.S. Food and Drug Administration (FDA) warns of significant risk of liver failure as a result of 26 such events related to Viekira Pack and Technivie which are anti-viral drugs used against Hepatitis C, produced by AbbVie Biopharmaceutical Company. The FDA notes that liver injury from these drugs appear to be in patients with moderate to severe liver impairment and occurs within four weeks of starting the drug. Read full story
Greg Vigna, MD, JD, a Certified Life Care Planner, and National Pharmaceutical Attorney states, “As academic rehabilitation physician, working closely with the transplant team, caring for liver transplant patients in an acute rehabilitation hospital there are few surgical procedures that produce the level of debility than liver transplantation.